Relief Therapeutics Holding has a Cash Ratio of 3.33. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Relief Therapeutics Holding's Cash Ratio or its related term are showing as below:
XSWX:RLF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.69 Max: 5.71
Current: 3.33
During the past 13 years, Relief Therapeutics Holding's highest Cash Ratio was 5.71. The lowest was 0.02. And the median was 0.69.
XSWX:RLF's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.94
vs XSWX:RLF: 3.33
Relief Therapeutics Holding (XSWX:RLF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Relief Therapeutics Holding Cash Ratio Related Terms
Relief Therapeutics Holding Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RLF vs KTTA, OSRH, LIMN: Cash Ratio Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (XSWX:RLF) has a Cash Ratio of 3.33 as of Jun. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Relief Therapeutics Holding and its competitors. This is 383% above median its historical median of 0.69. Over the past decade, Relief Therapeutics Holding's Cash Ratio has ranged from 0.02 to 5.71.
Is Relief Therapeutics Holding's Cash Ratio too high?
Relief Therapeutics Holding's current Cash Ratio of 3.33 is 383% above median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 5.71. The Biotechnology industry median Cash Ratio is 2.94. Relief Therapeutics Holding's value of 3.33 is 13.3% above this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Cash Ratio compare to KTTA and OSRH?
Relief Therapeutics Holding's Cash Ratio of 3.33 can be compared against companies in the Biotechnology industry. The industry median Cash Ratio is 2.94. Relief Therapeutics Holding's value of 3.33 is 13.3% above this benchmark. Historically, Relief Therapeutics Holding's own Cash Ratio has ranged from 0.02 to 5.71 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 2.94, Relief Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current Cash Ratio of 3.33 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current Cash Ratio is 3.33, which is 383% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Cash Ratio of 3.33. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Cash Ratio is 3.33, which is 383% above median its 10-year median of 0.69 and 13.3% above the Biotechnology industry median of 2.94. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Cash Ratio is 3.33 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Cash Ratio: 3.33 (383% above median its 10-year median of 0.69)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 13.3% above the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
